Lab
Ohiohealth Corporation
Ohiohealth Corporation was paid $44.08M by Medicaid between Jan 2018 and Dec 2024, across 324 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 8.7% of everything it billed.
33Billing provider infoOHIOHEALTH CORPORATION
COLUMBUS, OH 43214
COLUMBUS, OH 43214
33aNPI1710916945assigned 07/01/2006
33bProvider typeClinical Medical Laboratory
28Total paid$44.08M
24GClaims3,561,463
24DCodes billed324
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Ohio
Rank by total paid#7 of 116
Median peer was paid$313K
This provider vs. median141×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BROWNING, MICHAEL controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 464,007 | $5.83M | |
| 2019 | 474,757 | $5.50M | |
| 2020 | 460,177 | $7.00M | |
| 2021 | 563,688 | $8.20M | |
| 2022 | 563,203 | $6.79M | |
| 2023 | 628,370 | $6.52M | |
| 2024incomplete | 407,261 | $4.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.7% | 47,090 | 44,824 | $3.81M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.0% | 100,970 | 92,590 | $2.63M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.7% | 100,864 | 92,474 | $2.51M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 4.0% | 70,241 | 64,642 | $1.76M |
| 84443 | Thyroid stimulating hormone (TSH) | 3.8% | 142,184 | 134,405 | $1.68M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.7% | 36,321 | 29,641 | $1.64M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.2% | 76,539 | 72,784 | $1.43M |
| 80053 | Comprehensive metabolic panel | 3.2% | 186,758 | 172,038 | $1.41M |
| 80061 | Lipid panel | 2.8% | 131,754 | 125,292 | $1.24M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.6% | 58,588 | 55,838 | $1.15M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 2.6% | 3,642 | 3,320 | $1.13M |
| 87625 | 2.5% | 39,895 | 35,902 | $1.11M |
312 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.5% | 8,879 | $1.10M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 181,229 | $999K |
| 36415 | Collection of venous blood by venipuncture | 2.3% | 459,011 | $992K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.9% | 124,167 | $845K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.5% | 28,206 | $670K |
| 87480 | 1.4% | 42,511 | $610K | |
| 86703 | 1.3% | 59,810 | $590K | |
| 87510 | 1.3% | 42,501 | $579K | |
| 86803 | 1.2% | 52,033 | $532K | |
| 82607 | 1.2% | 49,883 | $524K | |
| 80055 | 1.1% | 13,661 | $471K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 79,956 | $469K |
| 87660 | <1% | 28,416 | $416K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,735 | $400K |
| 82728 | <1% | 40,983 | $383K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,288 | $376K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 2,749 | $360K |
| 87653 | <1% | 14,642 | $349K | |
| 85027 | <1% | 72,050 | $334K | |
| 87507 | <1% | 1,288 | $299K | |
| 82746 | <1% | 28,966 | $294K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 48,935 | $273K |
| 84702 | <1% | 23,072 | $264K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,291 | $259K |
| 86780 | <1% | 25,434 | $259K | |
| 84153 | <1% | 19,206 | $243K | |
| 83550 | <1% | 39,761 | $238K | |
| 87902 | <1% | 1,222 | $230K | |
| 83970 | <1% | 8,785 | $219K | |
| 86480 | <1% | 4,767 | $208K | |
| 84439 | <1% | 32,864 | $206K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,714 | $198K |
| 87522 | Neg quan hep c or qual rna | <1% | 6,500 | $195K |
| 84403 | <1% | 10,798 | $193K | |
| 83540 | <1% | 40,764 | $185K | |
| 87506 | <1% | 1,096 | $175K | |
| 87340 | <1% | 22,601 | $166K | |
| 87070 | <1% | 24,747 | $164K | |
| 83013 | <1% | 3,107 | $150K | |
| 87077 | <1% | 21,975 | $137K | |
| 80050 | General health panel | <1% | 5,197 | $131K |
| 87186 | <1% | 20,546 | $129K | |
| 82670 | <1% | 6,105 | $122K | |
| 82570 | <1% | 33,829 | $122K | |
| 88342 | <1% | 2,375 | $118K | |
| 80346 | <1% | 6,172 | $118K | |
| 83001 | <1% | 8,046 | $112K | |
| 80348 | <1% | 11,994 | $109K | |
| 82043 | <1% | 26,893 | $108K | |
| 80361 | <1% | 6,328 | $106K | |
| 86787 | <1% | 10,881 | $106K | |
| 84146 | <1% | 7,263 | $106K | |
| 86038 | <1% | 11,592 | $102K | |
| 82105 | <1% | 7,922 | $101K | |
| 80074 | <1% | 3,693 | $100K | |
| 86235 | <1% | 4,175 | $96K | |
| 83021 | <1% | 6,729 | $91K | |
| 84481 | <1% | 7,327 | $90K | |
| 82677 | <1% | 4,326 | $89K | |
| 88341 | <1% | 1,145 | $88K | |
| 83880 | <1% | 3,669 | $87K | |
| 81001 | <1% | 37,449 | $83K | |
| 87529 | <1% | 1,883 | $80K | |
| 86706 | <1% | 9,265 | $73K | |
| 83735 | <1% | 16,983 | $73K | |
| 83002 | <1% | 5,147 | $71K | |
| 86140 | <1% | 19,330 | $71K | |
| 87536 | <1% | 1,219 | $68K | |
| 84207 | <1% | 3,488 | $67K | |
| 82784 | <1% | 5,807 | $66K | |
| 82950 | <1% | 17,303 | $63K | |
| 84270 | <1% | 4,225 | $62K | |
| 0097U | <1% | 246 | $62K | |
| 80076 | <1% | 10,802 | $62K | |
| 86147 | <1% | 1,558 | $60K | |
| 80349 | <1% | 6,630 | $60K | |
| 80354 | <1% | 6,298 | $60K | |
| 80365 | <1% | 6,302 | $59K | |
| 86696 | <1% | 4,179 | $58K | |
| 86762 | <1% | 5,564 | $58K | |
| 80353 | <1% | 6,350 | $57K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,067 | $57K |
| 80373 | <1% | 6,146 | $57K | |
| 82565 | <1% | 15,580 | $56K | |
| 86336 | <1% | 4,471 | $55K | |
| 80356 | <1% | 6,142 | $55K | |
| 84154 | <1% | 4,216 | $54K | |
| 86592 | <1% | 17,401 | $54K | |
| 86704 | <1% | 6,076 | $53K | |
| 80358 | <1% | 5,883 | $53K | |
| 80321 | <1% | 4,508 | $53K | |
| 80359 | <1% | 5,868 | $53K | |
| 80324 | <1% | 5,285 | $50K | |
| 85652 | <1% | 24,899 | $48K | |
| 84425 | <1% | 3,275 | $48K | |
| 86334 | <1% | 3,337 | $46K | |
| 86376 | <1% | 4,328 | $46K | |
| 86850 | <1% | 8,027 | $46K | |
| 84460 | <1% | 12,170 | $45K | |
| 87205 | <1% | 14,204 | $45K | |
| 86200 | <1% | 4,772 | $45K | |
| 80069 | <1% | 8,461 | $44K | |
| 84450 | <1% | 12,097 | $44K | |
| 80345 | <1% | 4,808 | $44K | |
| 87147 | <1% | 6,749 | $43K | |
| 84144 | <1% | 2,993 | $43K | |
| 85610 | <1% | 15,304 | $42K | |
| 86146 | <1% | 1,161 | $41K | |
| 84550 | <1% | 12,276 | $39K | |
| 87081 | <1% | 8,233 | $39K | |
| 86695 | <1% | 3,905 | $38K | |
| 84402 | <1% | 1,697 | $38K | |
| 80362 | <1% | 2,684 | $38K | |
| 83520 | <1% | 2,633 | $37K | |
| 80355 | <1% | 3,935 | $36K | |
| 83992 | <1% | 2,912 | $36K | |
| 82248 | <1% | 10,965 | $36K | |
| 86431 | <1% | 8,486 | $36K | |
| 83521 | <1% | 1,498 | $35K | |
| 86800 | <1% | 3,019 | $35K | |
| 86225 | <1% | 3,535 | $34K | |
| 82951 | <1% | 3,671 | $33K | |
| 83615 | <1% | 7,690 | $33K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 886 | $32K |
| 82627 | <1% | 1,971 | $32K | |
| 86160 | <1% | 2,452 | $31K | |
| 80372 | <1% | 3,368 | $30K | |
| 86708 | <1% | 3,097 | $28K | |
| 83721 | <1% | 4,731 | $26K | |
| 83516 | <1% | 2,371 | $26K | |
| 84480 | <1% | 2,637 | $26K | |
| 84165 | <1% | 3,944 | $26K | |
| 86003 | <1% | 504 | $26K | |
| 82330 | <1% | 2,444 | $24K | |
| 86255 | <1% | 1,276 | $24K | |
| 83690 | <1% | 4,706 | $24K | |
| 88304 | <1% | 1,153 | $24K | |
| 82533 | <1% | 2,045 | $23K | |
| 84630 | <1% | 2,877 | $23K | |
| 82652 | <1% | 1,078 | $23K | |
| 83525 | <1% | 2,665 | $22K | |
| 82378 | <1% | 1,546 | $21K | |
| 80369 | <1% | 2,290 | $21K | |
| 80366 | <1% | 2,254 | $21K | |
| 84156 | <1% | 8,531 | $21K | |
| 84703 | <1% | 3,353 | $20K | |
| 84445 | <1% | 522 | $20K | |
| 80320 | <1% | 1,636 | $20K | |
| 80363 | <1% | 1,151 | $19K | |
| 80164 | <1% | 2,271 | $19K | |
| 83883 | <1% | 1,111 | $19K | |
| 83655 | <1% | 1,878 | $19K | |
| 81025 | <1% | 3,119 | $19K | |
| 82550 | <1% | 3,899 | $18K | |
| 84590 | <1% | 2,282 | $18K | |
| 82947 | <1% | 6,694 | $18K | |
| 84100 | <1% | 5,772 | $18K | |
| 82172 | <1% | 1,314 | $18K | |
| 83704 | <1% | 750 | $18K | |
| 85730 | <1% | 4,351 | $17K | |
| 85045 | <1% | 6,288 | $17K | |
| 86705 | <1% | 1,690 | $17K | |
| 86901 | <1% | 7,996 | $17K | |
| 83921 | <1% | 1,192 | $16K | |
| 86900 | <1% | 7,693 | $16K | |
| 80368 | <1% | 1,791 | $16K | |
| 87517 | <1% | 526 | $16K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 586 | $15K |
| 86765 | <1% | 1,424 | $15K | |
| 86735 | <1% | 1,387 | $15K | |
| 80323 | <1% | 1,626 | $14K | |
| 86364 | <1% | 1,685 | $14K | |
| 84520 | <1% | 5,326 | $14K | |
| 80051 | <1% | 3,421 | $14K | |
| 82310 | <1% | 3,595 | $13K | |
| 81596 | <1% | 330 | $12K | |
| 82977 | <1% | 2,344 | $12K | |
| 87254 | <1% | 668 | $12K | |
| 82040 | <1% | 3,706 | $12K | |
| 80197 | <1% | 1,949 | $12K | |
| 86769 | <1% | 326 | $12K | |
| 87106 | <1% | 1,597 | $12K | |
| 81241 | <1% | 272 | $11K | |
| 80360 | <1% | 1,179 | $11K | |
| 82952 | <1% | 3,652 | $11K | |
| 82140 | <1% | 1,013 | $10K | |
| 86304 | <1% | 736 | $10K | |
| 83498 | <1% | 523 | $10K | |
| 88185 | <1% | 51 | $10K | |
| 86709 | <1% | 1,210 | $10K | |
| 80325 | <1% | 987 | $9K | |
| 87075 | <1% | 1,405 | $9K | |
| 84436 | <1% | 1,924 | $9K | |
| 80364 | <1% | 536 | $9K | |
| 84681 | <1% | 638 | $9K | |
| 86870 | <1% | 402 | $9K | |
| 80352 | <1% | 1,003 | $9K | |
| 85018 | <1% | 4,795 | $8K | |
| 84134 | <1% | 886 | $8K | |
| 86812 | <1% | 509 | $8K | |
| 86481 | <1% | 121 | $8K | |
| 85613 | <1% | 1,206 | $8K | |
| 81003 | <1% | 4,005 | $8K | |
| 80177 | <1% | 725 | $7K | |
| 84432 | <1% | 628 | $7K | |
| 88112 | <1% | 348 | $7K | |
| 82150 | <1% | 1,542 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 612 | $7K |
| 88307 | <1% | 56 | $7K | |
| 85007 | <1% | 2,529 | $7K | |
| 86036 | <1% | 416 | $7K | |
| 85379 | <1% | 891 | $6K | |
| 85014 | <1% | 3,557 | $6K | |
| 86039 | <1% | 670 | $6K | |
| 82525 | <1% | 715 | $6K | |
| 82785 | <1% | 454 | $5K | |
| 80178 | <1% | 1,126 | $5K | |
| 84132 | <1% | 1,664 | $5K | |
| 82077 | <1% | 916 | $5K | |
| 84075 | <1% | 1,725 | $5K | |
| 82390 | <1% | 677 | $5K | |
| 84155 | <1% | 2,007 | $5K | |
| 80371 | <1% | 488 | $5K | |
| 86677 | <1% | 461 | $5K | |
| 80357 | <1% | 461 | $4K | |
| 80175 | <1% | 424 | $4K | |
| 80336 | <1% | 439 | $4K | |
| 87563 | <1% | 180 | $4K | |
| 82088 | <1% | 172 | $4K | |
| 82247 | <1% | 1,606 | $4K | |
| 87350 | <1% | 529 | $4K | |
| 80332 | <1% | 429 | $4K | |
| 88184 | <1% | 97 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 359 | $4K |
| 81050 | <1% | 1,602 | $4K | |
| 83519 | <1% | 128 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 139 | $4K |
| 80343 | <1% | 397 | $4K | |
| 82024 | <1% | 132 | $4K | |
| 81240 | <1% | 94 | $4K | |
| 86618 | <1% | 308 | $4K | |
| 84478 | <1% | 906 | $4K | |
| 85240 | <1% | 285 | $4K | |
| 86707 | <1% | 448 | $3K | |
| 86381 | <1% | 214 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 83 | $3K |
| 83010 | <1% | 363 | $3K | |
| 88312 | <1% | 52 | $3K | |
| 82166 | <1% | 120 | $3K | |
| 80202 | <1% | 277 | $3K | |
| 81206 | <1% | 44 | $3K | |
| 82523 | <1% | 234 | $2K | |
| 85660 | <1% | 487 | $2K | |
| 84305 | <1% | 117 | $2K | |
| 84410 | <1% | 60 | $2K | |
| 86341 | <1% | 104 | $2K | |
| 86360 | <1% | 56 | $2K | |
| 82239 | <1% | 131 | $2K | |
| 87210 | <1% | 631 | $2K | |
| 86015 | <1% | 254 | $2K | |
| 82103 | <1% | 203 | $2K | |
| 86593 | <1% | 505 | $2K | |
| 84244 | <1% | 106 | $1K | |
| 82679 | <1% | 85 | $1K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 13 | $1K |
| 83020 | <1% | 122 | $1K | |
| 83090 | <1% | 121 | $1K | |
| 87206 | <1% | 319 | $1K | |
| 86665 | <1% | 51 | $1K | |
| 84466 | <1% | 119 | $1K | |
| 83695 | <1% | 117 | $970.93 | |
| 85306 | <1% | 80 | $937.94 | |
| 81329 | <1% | 13 | $883.09 | |
| 86361 | <1% | 53 | $870.09 | |
| 87102 | <1% | 148 | $809.00 | |
| 82274 | <1% | 52 | $808.55 | |
| 83835 | <1% | 66 | $789.06 | |
| 82664 | <1% | 17 | $771.01 | |
| 82164 | <1% | 75 | $700.30 | |
| 85303 | <1% | 73 | $654.58 | |
| 84484 | <1% | 84 | $630.42 | |
| 85576 | <1% | 13 | $629.16 | |
| 88302 | <1% | 26 | $605.43 | |
| 87338 | <1% | 49 | $585.92 | |
| 86256 | <1% | 59 | $498.86 | |
| 80347 | <1% | 19 | $434.11 | |
| 86308 | <1% | 93 | $419.17 | |
| 82465 | <1% | 108 | $378.11 | |
| 83993 | <1% | 24 | $353.30 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 329 | $349.02 |
| 87088 | <1% | 39 | $260.51 | |
| 80156 | <1% | 26 | $258.63 | |
| 85300 | <1% | 28 | $246.68 | |
| 83789 | <1% | 16 | $228.24 | |
| 86301 | <1% | 14 | $209.47 | |
| 86694 | <1% | 14 | $169.44 | |
| 82668 | <1% | 12 | $161.69 | |
| 86664 | <1% | 13 | $144.63 | |
| 85049 | <1% | 41 | $131.94 | |
| 84446 | <1% | 13 | $129.92 | |
| 80201 | <1% | 14 | $123.75 | |
| 83068 | <1% | 16 | $111.57 | |
| 80185 | <1% | 14 | $110.35 | |
| 82270 | <1% | 25 | $71.68 | |
| 85384 | <1% | 16 | $60.02 | |
| 80339 | <1% | 18 | $17.64 | |
| 3052F | 0% | 14 | $0.00 | |
| 3044F | 0% | 130 | $0.00 | |
| 81511 | 0% | 15 | $0.00 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 47 | $0.00 |
| 3051F | 0% | 29 | $0.00 | |
| 3046F | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWNING, MICHAEL (CFO, OHIOHEALTH)
| Provider | Location | Paid |
|---|---|---|
| Ohiohealth Corporation | Columbus, OH | $214.99M |
| Ohiohealth Corporation | Columbus, OH | $76.95M |
| Ohiohealth Corporation | Columbus, OH | $72.29M |
| Medcentral Health System | Mansfield, OH | $36.92M |
| Marion General Hospital, INC. | Marion, OH | $36.47M |
| Sheltering Arms Hospital Foundation, INC. | Athens, OH | $26.88M |
| Ohiohealth Berger Hospital LLC | Circleville, OH | $16.38M |
| Ohiohealth Corporation | Dublin, OH | $11.81M |
| Grady Memorial Hospital | Delaware, OH | $9.51M |
| Hardin Memorial Hospital | Kenton, OH | $7.27M |
| Medcentral Health System | Mansfield, OH | $3.13M |
| Madison Family Health Corporation | London, OH | $1.03M |
| Marion General Hospital, INC. | Marion, OH | $683K |
| Medcentral Health System | Mansfield, OH | $477K |
| Sheltering Arms Hospital Foundation | Athens, OH | $435K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.